These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 37424859)

  • 41. Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    Seto WK; Yuen MF
    J Gastroenterol; 2017 Feb; 52(2):164-174. PubMed ID: 27637587
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice.
    El Sherif O; Dhaliwal A; Newsome PN; Armstrong MJ
    Expert Rev Gastroenterol Hepatol; 2020 Mar; 14(3):197-205. PubMed ID: 32064966
    [No Abstract]   [Full Text] [Related]  

  • 44. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
    Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
    World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study.
    Lee HJ; Lee DC; Kim CO
    Front Endocrinol (Lausanne); 2021; 12():599339. PubMed ID: 33868162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adiponectin-leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance.
    Lu CW; Yang KC; Chi YC; Wu TY; Chiang CH; Chang HH; Huang KC; Yang WS
    Ann Med; 2023 Dec; 55(1):634-642. PubMed ID: 36790383
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease.
    Chun HS; Lee M; Lee HA; Oh SY; Baek HJ; Moon JW; Kim YJ; Lee J; Kim H; Kim HY; Yoo K; Kim TH; Kim SU
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):358-369.e12. PubMed ID: 34998993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease.
    Fuchs A; Samovski D; Smith GI; Cifarelli V; Farabi SS; Yoshino J; Pietka T; Chang SW; Ghosh S; Myckatyn TM; Klein S
    Gastroenterology; 2021 Sep; 161(3):968-981.e12. PubMed ID: 34004161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B.
    Han E; Lee YH; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH; Kim SU
    Aliment Pharmacol Ther; 2018 Aug; 48(3):300-312. PubMed ID: 29920701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011).
    Lee YH; Jung KS; Kim SU; Yoon HJ; Yun YJ; Lee BW; Kang ES; Han KH; Lee HC; Cha BS
    J Hepatol; 2015 Aug; 63(2):486-93. PubMed ID: 25772036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Value of Visceral Fat Area and Resting Energy Expenditure in Assessment of Metabolic Characteristics in Obese and Lean Nonalcoholic Fatty Liver Disease.
    Ye Q; Yan J; Xiao HJ; Han T
    Turk J Gastroenterol; 2021 Feb; 32(2):116-122. PubMed ID: 33960934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.
    Sookoian S; Pirola CJ
    Aliment Pharmacol Ther; 2018 Jan; 47(1):16-25. PubMed ID: 29083036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA.
    Wijarnpreecha K; Kim D; Raymond P; Scribani M; Ahmed A
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1121-1128. PubMed ID: 30888971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential Impact of Weight Loss on Nonalcoholic Fatty Liver Resolution in a North American Cohort with Obesity.
    Rachakonda V; Wills R; DeLany JP; Kershaw EE; Behari J
    Obesity (Silver Spring); 2017 Aug; 25(8):1360-1368. PubMed ID: 28605159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease.
    Kang MK; Kim KO; Kim MC; Park JG; Jang BI
    Dig Dis; 2020; 38(6):507-514. PubMed ID: 32135539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship Between Protein Intake and Sarcopenia in the Elderly with Nonalcoholic Fatty Liver Disease Based on the Fourth and Fifth Korea National Health and Nutrition Examination Survey.
    Hong J; Shin WK; Lee JW; Kim Y
    Metab Syndr Relat Disord; 2021 Oct; 19(8):452-459. PubMed ID: 34255575
    [No Abstract]   [Full Text] [Related]  

  • 58. Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications.
    Fernández-Mincone T; Contreras-Briceño F; Espinosa-Ramírez M; García-Valdés P; López-Fuenzalida A; Riquelme A; Arab JP; Cabrera D; Arrese M; Barrera F
    Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1141-1157. PubMed ID: 32811209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.
    De Munck TJI; Verhaegh P; Lodewick T; Bakers F; Jonkers D; Masclee AAM; Verbeek J; Koek GH
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101500. PubMed ID: 32828745
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.